Neurocrine Biosciences, Inc. (NBIX)
| Previous Close | 133.66 |
| Open | 140.62 |
| Bid | 139.46 x 100 |
| Ask | 139.73 x 100 |
| Day's Range | 139.26 - 145.00 |
| 52 Week Range | 89.04 - 148.37 |
| Volume | |
| Avg. Volume | 864,390 |
| Market Cap | 14.042B |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 56.52 |
| EPS (TTM) | 2.47 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 29, 1995 |
| 1y Target Est | 151.96 |
Investor's Business DailyNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
Top-notch biotech stock Neurocrine launched higher Tuesday after the company's depression treatment succeeded in a midstage study.
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
Insider Monkey10 Best Performing Biotech ETFs in 2024
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
